Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CTAG1B (Cancer/testis antigen 1B)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

EarlyCDT®-Lung

EarlyCDT®-Lung

›

CTAG1B expression	Synovial Sarcoma	CTAG1B expression	Synovial Sarcoma	TBI-1301 Sensitive: C2 – Inclusion Criteria TBI-1301 Sensitive : C2	TBI-1301 Sensitive: C2 – Inclusion Criteria TBI-1301 Sensitive : C2
LAG3 expression + CTAG1B expression	Non Small Cell Lung Cancer	LAG3 expression + CTAG1B expression	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
PD-L1 overexpression + LAG3 expression + CTAG1B expression	Non Small Cell Lung Cancer	PD-L1 overexpression + LAG3 expression + CTAG1B expression	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
CTAG1B antibody elevation	Melanoma	CTAG1B antibody elevation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CTAG1B antibody elevation + XAGE1 antibody elevation	Non Small Cell Lung Cancer	CTAG1B antibody elevation + XAGE1 antibody elevation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CTAG1B antibody elevation	Non Small Cell Lung Cancer	CTAG1B antibody elevation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CTAG1B overexpression	Mucosal Melanoma	CTAG1B overexpression	Mucosal Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
HLA-A*02:01 + CTAG1B expression	Soft Tissue Sarcoma	HLA-A*02:01 + CTAG1B expression	Soft Tissue Sarcoma	TAEST16001 Sensitive: C3 – Early Trials TAEST16001 Sensitive : C3	TAEST16001 Sensitive: C3 – Early Trials TAEST16001 Sensitive : C3
CTAG1B expression + CTAG2 expression	Non Small Cell Lung Cancer	CTAG1B expression + CTAG2 expression	Non Small Cell Lung Cancer	GSK3377794 Sensitive: D – Preclinical GSK3377794 Sensitive : D	GSK3377794 Sensitive: D – Preclinical GSK3377794 Sensitive : D